DURHAM, N.C. & SEATTLE-- November 13, 2023--Pioneering epigenome editing company Tune Therapeutics has announced it is working on a new and potentially curative approach to treating chronic HBV infection. The...
New Pappas Capital Fund Makes First Investment
News | 05. 24. 2017
OrphoMed
Research Triangle Park, NC, May 24, 2017 – Pappas Capital, a life science venture capital firm, announced today that its new fund, Pappas Ventures V, recently invested in OrphoMed, a clinical stage company that is developing best-in-class therapies for treatment of inadequately-controlled gastrointestinal disorders. The investment in OrphoMed is the first investment by the new Pappas Ventures fund.
